Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Proteasome inhibitors in myeloma treatment

Rakesh Popat • 12 Jun 2020
EHA 2020
Multiple Myeloma Bortezomib Carfilzomib Dexamethasone Ixazomib Lenalidomide
ENDURANCE

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of the University College London Hospitals, London, UK, explores the use of proteasome inhibitors in multiple myeloma treatment as well as new approaches investigated in the ENDURANCE study (NCT01863550), comparing RVD and kRD. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Rakesh Popat

2:06
The optimal sequencing of CAR-T and other immunotherapies in multiple myeloma
Rakesh Popat • 16 Feb 2024
3:46
'Clinical case discussions' session rundown: HLH/MAS, aseptic meningitis, & CAR-NK cells in MM
Rakesh Popat • 16 Feb 2024
1:30
Selecting patients with myeloma for CAR-T: important clinical considerations
Rakesh Popat • 16 Feb 2024
1:14
The potential of CELMoDs for the treatment of R/R multiple myeloma
Rakesh Popat • 10 Dec 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals